


GONADAL HORMONES AND THEIR INHIBITORS

By:

Azza Osman Yousif
MSc in clinical pharmacy

- ❖ Are the steroids produced in the ovaries and testis:
 - ❑ Estrogen
 - ❑ Progestin
 - ❑ Testosterone



Endometrium sheds (thins)

Endometrium thickens

Thickness of endometrium (uterine lining)

Ovary: follicle releases egg then collapses

Gonadotropic hormone levels (LH & FSH)

Ovarian hormone levels (estrogen and progesterone)

Body temperature (°C) rises at ovulation


37.0°
36.5°
36.0°

Day

Period starts

Period ends

Ovulation (egg released)



0 5 10 14 20 25 28

- ❑ The menstrual cycle starts with menstruation.
- ❑ Hypothalamus: Gonadotrophin-releasing hormone >>>> acts on the anterior pituitary >>>> release follicle-stimulating hormone (FSH) and luteinising hormone (LH).

- FSH and LH stimulate follicle development in the ovary. FSH is the main hormone stimulating oestrogen release.

Follicular phase

- LH stimulates ovulation at mid-cycle and is the main hormone controlling subsequent progesterone secretion from the corpus luteum.

Luteal phase

- ❑ Oestrogen :controls the **proliferative phase** of the endometrium and has **negative feedback effects** on the anterior pituitary.
- ❑ Progesterone: controls the **later secretory phase**, and has **negative feedback effects** on both the hypothalamus and anterior pituitary.
- ❑ If a fertilised ovum is implanted, the **corpus luteum** continues to secrete progesterone.

- After implantation, **human chorionic gonadotrophin (HCG)** from the chorion becomes important, and later in pregnancy progesterone, HCG and other hormones are secreted by the placenta.

DRUGS AFFECTING REPRODUCTIVE FUNCTION

I) ESTROGENS

- Oestrogens : synthesized from **cholesterol**, by:
 - **Ovaries***
 - Placenta
 - Testis and adrenal cortex (small amounts)

A) Endogenous Estrogens :
***(oestradiol**, oestrone and oestriol)**

B) Exogenous estrogens:

- ❑ Mestranol, ethinylestradiol, diethylstilbestrol
- ❑ Oral, transdermal, intramuscular, implantable and topical
- ❑ Single agents or combined with progestogen.

- Natural oestrogens are rapidly metabolised in the liver, whereas **synthetic oestrogens are degraded less rapidly.**

MECHANISM OF ACTION:

- ◉ Involves interaction with **nuclear receptors** (ER α or ER β) in target tissues, resulting in modification of **gene transcription**.
- ◉ Some of the **rapid vascular and metabolic effects** of oestrogens are mediated by a **G protein-coupled [o]estrogen receptor (GPER)**.

EXOGENOUS ESTROGEN EFFECTS

Uses : Estrogens are used in the treatment of hypogonadism in young females.

- Estrogen is essential for normal female reproductive development.

Side effects : premature closure of the epiphyses of the long bones and short stature

Uses: as contraceptives in combination with progestins

- Continuous administration of estrogen, especially in combination with a progestin, inhibits the secretion of **gonadotropins** from the anterior pituitary.

Side effects : dose dependent nausea, breast tenderness, increased risk of **migraine headache**, **thromboembolic events** (eg, deep vein thrombosis), gallbladder disease, hypertriglyceridemia, and hypertension

- ◉ *In adults with primary amenorrhoea: oestrogen, given cyclically with a progestogen, induces an artificial cycle.*

Uses: as hormonal
replacement therapy
(HRT)

- ⊙ Reduce bone resorption ,
- ⊙ Enhances the coagulability of blood
- ⊙ Increases plasma triglyceride levels while reducing (LDL) cholesterol and increasing (HDL) cholesterol.

Side effects : increases the risk of endometrial cancer , combination with progestin reduce this risk .

OVERALL SIDE EFFECTS

- Breast tenderness, nausea, vomiting, anorexia, retention of salt and water with resultant oedema, and increased risk of thromboembolism.
- Oestrogen causes endometrial hyperplasia unless given cyclically with a progestogen.

- For postmenopausal replacement therapy, oestrogens cause menstruation-like bleeding.
- Carcinoma of the vagina was more common in young women whose mothers were given diethylstilbestrol in early pregnancy.

C) SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM)

- Are **agonist** in some tissues and **antagonist** in others.

1. Tamoxifen :

- **Antagonist at the breast** tissues (To treat oestrogen-sensitive breast cancer).
- **Agonist at bone** : prevent from osteoporosis.
- **Agonist at the uterus** : increase risk of endometrial cancer.
- Increase the risk of **Thromboembolic events**

- 2. Raloxifene: same as tamoxifen but has no effect on **endometrial tissue**.
- **Antagonist at the** breast tissues
- **Antagonist** at the uterus
- **Agonist** at bone
- Approved for prevention and **treatment**
- **of osteoporosis**.

D) ANTI-ESTROGEN

Clomiphene:

- ❑ Approved to induce **ovulation**
- ❑ Selectively block estrogen receptors in the pituitary, **reduces negative feedback and increases FSH and LH output.**
- ❑ **Twins are common**, but multiple pregnancy is unusual.

Fulvestrant:

- Is a pure estrogen receptor antagonist (in all tissues).

II) PROGESTINS

- **Progesterone** is the major progestin in humans.

Maintain pregnancy

- Progesterone induces secretory changes in the endometrium and is required for the **maintenance of pregnancy.**

Causes significant weight gain as a
Side effect

- Affect carbohydrate metabolism and stimulate fat deposition .

Used as contraceptives in
combination with
estrogen or alone

- Inhibit ovulation

- Progestogens act on nuclear receptors.
- The **density** of progesterone receptors is controlled by **oestrogens**.

PROGESTIN PREPARATIONS

1. The **naturally occurring** hormone and its derivatives: (e.g. hydroxyprogesterone, medroxyprogesterone, dydrogesterone).
- Are available for oral administration, intramuscular injection or administration via the vagina or rectum.


2. Testosterone derivatives :(e.g. Norethisterone, norgestrel and ethynodiol) can be given orally. (2nd generation)

- ❑ The first two have some **androgenic activity** and are metabolised to give oestrogenic products.
- ❑ Newer progestogens include **desogestrel** and **gestodene**. (3rd generation)

PROGESTIN ANTAGONIST:

- ◉ **Mifepristone:**
- ◉ Partial agonist at progesterone receptors.
It sensitises the uterus to the action of prostaglandins.
- ◉ The antiprogestogen **Mifepristone**, in combination with prostaglandin analogues, is an effective medical alternative to surgical termination of early pregnancy.
(abortifacient).

III) HORMONAL CONTRACEPTIVES



Oral pills, long-acting injections, transdermal patches, vaginal rings, and intrauterine devices (IUDs)

- A. Combined oral contraceptives (COC):
monophasic, biphasic and triphasic
- B. Progestin only Contraceptives
- C. Others: Postcoital contraception , Long acting progestin only contraception

A) COMBINED ORAL CONTRACEPTIVES (COC):

- ◉ **Ethinylestradiol, is the oestrogen in most combined preparations.**
- ◉ This combined pill is taken for 21 consecutive days followed by **7 pill-free days**, which causes a withdrawal bleed.

MECHANISM OF ACTION :

- **Oestrogen: inhibits secretion of FSH** via negative feedback on the anterior pituitary, and thus suppresses **development of the ovarian follicle**.
- **Progestogen: inhibits secretion of LH** and thus **prevents ovulation**; it also makes the cervical mucus less suitable for the passage of sperm.
- **Oestrogen and progestogen** act in concert to alter the endometrium in such a way as to **discourage implantation**.

- ◉ **Other uses :**
- ◉ Acne treatment, hirsutism, dysmenorrhea, and endometriosis.
- ◉ Users of combination hormonal contraceptives have reduced risks of ovarian cysts, ovarian and endometrial cancer.

SIDE EFFECTS :

- ◉ Weight gain, owing to fluid retention or an anabolic effect, or both.
- ◉ Mild nausea, flushing, dizziness, depression or irritability.
- ◉ Skin changes (e.g. Acne and/or an increase in pigmentation).
- ◉ Amenorrhoea of variable duration on cessation of taking the pill.

○ **CVD risks:**

- With second-generation pills (oestrogen content less than 50 µg), the risk of thromboembolism is small.

- Risk increased with the 3rd generation combination (**desogestrel or gestodene**), smoking, obesity, hypertention, and long-continued use of the pill, especially in women over 35 years of age.

- ⦿ **Hypertension:**

- A small proportion of women develop **reversible** hypertension. **Blood pressure is therefore monitored** when oral contraceptive treatment is started.

- ⦿ **Cancer risks:**

- Ovarian and endometrial cancer risk is *reduced*.

B) PROGESTIN ONLY PILLS

- ◉ The progestogen-only pill is taken **continuously**. It differs from the combined pill in that the contraceptive effect is **less reliable** and is mainly a result of the alteration of cervical mucus. Irregular bleeding is common.

C) OTHERS:

- ◉ A) **Postcoital pill : levonorgestrel, alone or combined with oestrogen, is effective if taken within 72 h of unprotected sexual intercourse. And repeated after 12 hrs later.**

- ◉ B) **long acting progestin only :**
 - ❑ **Medroxyprogesterone >> injected IM**
 - ❑ **Levonorgestrel >> Implanted subcutaneously>>> 5 years activity**
 - ❑ **Levonorgestrel>>> impregnated intrauterine system provides prolonged, reliable contraception**

HOME WORK

- ◉ **Study the following:**
- ❑ **Contraceptive use in patients with epilepsy**
- ❑ **Androgens and the hormonal control of the male reproductive system.**
- ❑ **Drugs acting on the uterus (stimulant and inhibitors of contraction).**
- ❑ **GONADOTROPHIN-RELEASING HORMONE: (AGONISTS AND ANTAGONISTS).**

SEMINARS' GROUPS

□ Tuesday 18/2 :

- 1-12 : Contraceptive use in females with epilepsy
- 13-24: Androgens and the hormonal control of the male reproductive system
- 25-36: Drugs acting on the uterus (stimulant and inhibitors of contraction)
- 37-48: GONADOTROPHIN-RELEASING HORMONE: (AGONISTS AND ANTAGONISTS).


□ **Thursday 20/2:**

- **49-61: Pharmacokinetics**
- **62-73: Pharmacodynamics**
- **74-85: ANS (Parasympathetic and sympathetic, agonists and antagonists).**
- **86-97: Local hormones Pharmacology**

□ **Tuesday 25/2:**

- **98-109: Blood pharmacology**
- **110-121: Bone pharmacology**
- **122-133: Steroids pharmacology**
- **134-146: NSAIDs**

◎ Summary



If it is important to you, you
will find a way. If not, you'll
find an excuse.

Ryan Blair

THANK YOU

Good luck